Red Willow Hospice Unveils New Psychedelic Treatments

Why It Matters

The program demonstrates how hospice care can integrate emerging psychedelic therapies to improve quality of life, potentially setting a national standard for end‑of‑life treatment models.

Key Takeaways

• Red Willow Hospice to launch psilocybin and ketamine therapies in December
• Grant from Healing Hearts provides $500,000 for psychedelic end‑of‑life care
• First hospice cohort in Conscious Physicians Psychedelics Academy training program
• Psilocybin legalized for medical use in NM June 2025, enabling hospice use
• Treatments offered at no cost to patients via grant funding

Pulse Analysis

The convergence of psychedelic research and hospice care is reaching a tipping point as state legislation and private funding unlock new treatment pathways. New Mexico’s June 2025 law legalizing psilocybin for medical use, particularly for end‑of‑life care, creates a regulatory backdrop that few states have yet to emulate. This legal shift, combined with growing clinical evidence that psychedelics can alleviate existential anxiety and depression, positions hospice providers to explore therapies traditionally reserved for psychiatric settings. For industry observers, the policy change signals a broader acceptance of psychedelics within mainstream healthcare.

Red Willow Hospice’s rollout leverages a $500,000 grant from Healing Hearts Changing Minds and a comprehensive training partnership with the Conscious Physicians Psychedelics Academy. As the first hospice cohort in the Academy’s program, staff—including physicians, nurses, social workers, and spiritual care coordinators—are receiving nine months of interdisciplinary education on safe dosing, emergency protocols, and ethical considerations. The hospice also collaborates with the New Mexico Department of Health to codify best‑practice guidelines, ensuring that the integration of psilocybin and ketamine meets rigorous safety standards while remaining patient‑centered.

If successful, Red Willow’s model could catalyze a wave of similar initiatives across rural and urban hospice networks. By offering the therapies at no cost to patients, the organization addresses a critical barrier—financial accessibility—that has limited broader adoption. The program’s emphasis on research, outcome tracking, and policy development may provide a replicable framework for insurers, regulators, and providers seeking to incorporate psychedelic medicine into palliative care portfolios. As the industry watches, the hospice’s experience could shape reimbursement discussions and influence future legislative efforts nationwide.